Abstract: A salt of formula ##STR1## where X denotes a group of formula ##STR2## Y denotes a group of formula ##STR3## and R denotes the residue of an aliphatic or cycloaliphatic sulphonic acid having at least 3 carbon atoms after removal of a --SO.sub.3 H group therefrom.

Abstract: Allophanate-modified MDI which is a storage stable liquid at 25.degree. C. is produced by reacting a monoisocyanate and an organic material having at least two hydroxyl groups and a molecular weight of from about 60 to about 6,000 to form a urethane. The urethane is then reacted with and isomeric mixture of MDI in an amount such that the product isocyanate will have an NCO content of from about 12 to about 30%. The isomeric mixture of MDI is composed of 4,4'-diphenylmethane diisocyanate containing from 0 to about 60% by weight 2,4'-MDI and less than 6% by weight of the 2,2'-MDI. This allophanate-modified MDI is further reacted with an organic isocyanate-reactive material to produce an allophanate-modified MDI prepolymer containing urethane, urea and/or biuret groups having an NCO content which is generally from about 5 to about 29% by weight. The prepolymers of this invention are particularly useful in reaction injection molding processes because they give molded articles having improved flex modulus.

Abstract: A new compound is disclosed which can be used as a builder. The compound is cysteic monosuccinic acid (CMS) and its salts as well as methods of making CMS.

Abstract: There are disclosed (+)2-benzoyl-3-[prop-2(S)-yl)amino] acrylate derivatives of following the formula and a method for the preparation of the same; ##STR1## wherein X is a halogen; X.sub.1 and X.sub.2 are independently selected from a halogen and a nitro; and R and R.sub.1 each is an alkyl group containing 1 to 4 carbon atoms.

Abstract: A method for producing a (2-alkyl)acryloyl isocyanate of the formula ICH.sub.2 .dbd.C(R.sup.1)--C(O)--NCO (I)wherein R.sup.1 is defined herein, from the dissociation of a compound of formula III ##STR1## wherein R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are defined herein and wherein the dissociation of the compound of formula III produces the compound of formula I and a compound of formula II(R.sup.3) (R.sup.4)C.dbd.N--R.sup.2 (II)wherein R.sup.3, R.sup.4 and R.sup.2 are defined herein.

Abstract: A process for preparing acetic acid from methanol and carbon monoxide or a mixed gas of carbon monoxide with hydrogen, which process comprises contacting methanol with a gaseous component selected from a group consisting of carbon monoxide and a mixed gas of carbon monoxide with hydrogen of 2% by volume or less in the presence of a carbon-supported rhodium metal catalyst and methyl iodide promoter in vapor phase under the conditions of a reaction temperature of 180.degree.-220.degree. C., a reaction pressure of 5-10 kg/cm.sup.2 .multidot.G, and a weight of catalyst to feed gas flow rate ratio (W/F) of 10-20 g.multidot.h/mole; and a process for preparing acetic acid from methanol and carbon monoxide, which process comprises contacting methanol with carbon monoxide in the presence of a carbon-supported rhodium metal catalyst, methyl iodide promoter and water in vapor phase.

Abstract: This invention relates to compounds of formula (I), in which R denotes a hydrogen atom or a methoxy radical. The invention also concerns the salts of said compounds, their racemic forms, their enantiomers, the preparation of said derivatives and drugs containing same.

Abstract: The present invention relates to novel derivatives of 3-hydroxyanthranilic acid, 3-HANA of general formula (I), wherein R.sup.1 and R.sup.2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R.sup.3, R.sup.4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and Z-R.sup.5 wherein Z is selected from CH.sub.n, NH.sub.m, O, S, SO.sub.2 and CO wherein n=1 or 2; m=0 or 1 and R.sup.5 is selected from alkyl, aryl and fluoroalkyl; or R.sup.3 and R.sup.4 together form a saturated or unsaturated ring system Y-V-Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C.sub.1 -C.sub.3 alkylene or alkenylene, --N.dbd., --N.dbd.N-- and (a), wherein R.sub.7 .dbd.

Abstract: The present invention is concerned with compounds of formula (I) ##STR1## wherein Ar is a mono- or bicyclic aromatic group optionally containing one or two heteroatoms independently selected from nitrogen, oxygen and sulphur, said group being optionally substituted by one or more atoms or groups independently selected from halogen, nitro, amino, --NRR.sup.1 where R and R.sup.1 are independently selected from hydrogen, C.sub.1-8 alkyl and C.sub.1-8 alkanoyl, cyano, carboxyalkoxy, alkoxycarbonylalkoxy, C.sub.1-8 alkyl (including cycloalkyl and cycloalkylalkyl), C.sub.1-8 alkoxy (including cycloalkoxy and cycloalkylalkoxy), C.sub.

Abstract: Compounds of the formula: ##STR1## wherein R is CH.sub.2 X or CHX.sub.2 and X is chloro or bromo and R.sup.1 is chloro, bromo or nitro which are useful as intermediates for preparing herbicidal 2-(2'-substituted)-4'-(alkylsulfonyl)benzoyl-1,3-cyclohexanedione compounds.

Abstract: Polyoxyalkylene glycol monoesters of carboxylic acids are prepared by a process in which tetrahydrofuran or a mixture of tetrahydrofuran with a total of not more than 95 mol %, based on the amount of tetrahydrofuran used, of one or more comonomers from the group consisting of the cyclic ethers and acetals is polymerized in the absence of water and in the presence of a carboxylic acid and of an anhydrous heteropolyacid catalyst.

Abstract: This invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier, an angiotensin II receptor antagonist and a second agent selected from a diuretic, a calcium channel blocker, a .beta.-adrenoceptor blocker, a renin inhibitor, or an angiotensin converting enzyme inhibitor and a method of treating hypertension.

Abstract: The present invention describes compounds, methods and compositions effective to treat mast cell mediated inflammatory conditions, such as conjunctivitis, asthma and allergic rhinitis. The compounds of the invention comprise novel mono- and di-aminomethylbenzyl, aminobenzyl, guanidylbenzyl and benzyl tryptase inhibitors. The compositions for treating mast cell mediated inflammatory conditions include oral, inhalant and topical preparations as well as devices comprising such preparations.

Abstract: Compounds of general formula (I) wherein R.sup.1 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkenyl, phenyl, phenyl(C.sub.1 -C.sub.6)alkyl, C.sub.1 -C.sub.6 alkylthiomethyl, phenylthiomethyl, substituted phenylthiomethyl, phenyl(C.sub.1 -C.sub.6)alkylthiomethyl or heterocyclylthiomethyl group; or R.sup.1 represents --S--R.sup.x wherein R.sup.x represents a group .alpha.; R.sup.2 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkenyl, phenyl(C.sub.1 -C.sub.6)alkyl, cycloalkyl(C.sub.1 -C.sub.6)alkyl, or cycloalkenyl(C.sub.1 -C.sub.6)alkyl; R.sup.3 represents an amino acid side chain or a C.sub.1 -C.sub.6 alkyl, benzyl, (C.sub.1 -C.sub.6)alkoxybenzyl, benzyloxy(C.sub.1 -C.sub.6)alkyl or benzyloxybenzyl group; R.sup.4 represents a hydrogen atom or a methyl group; R.sup.5 represents a group (CH.sub.2).sub.n A; or R.sup.4 and R.sup.5 together represent a group .beta.; Q represents CH.sub.

Abstract: The present invention relates to a compound of formula ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in whichX is --O--CO--, --NH--CO--, --CS--NH--, --CO--O--, --CO--NH--, --COS--, --SCO--, --SCH.sub.2 --, --CH.sub.2 --CH.sub.2 --, --C.tbd.C--, --CH.sub.2 --NH--, --COCH.sub.2 --, --NHCS--, --CH.sub.2 S--, --CH.sub.2 O--, --OCH.sub.2 --, --NHCH.sub.2 -- or --CR.sup.5 .dbd.CR.sup.6 --;R.sup.m and R.sup.k are independently hydrogen, halogen, C.sub.1-6 alkyl, hydroxy, C.sub.1-6 alkyloxy or nitro;n is zero or one;R.sup.4 is --(CH.sub.2).sub.t --Y, C.sub.1-6 alkyl, or C.sub.3-6 cycloalkyl;R.sup.1 is --CO.sub.2 Z, C.sub.1-6 alkyl, CH.sub.2 OH, --CONHR.sup.y, or CHO;R.sup.2 and R.sup.3 are independently hydrogen or C.sub.1-6 alkyl;R.sup.a and R.sup.b are independently hydrogen or C.sub.1-6 alkyl; but when n is one, R.sup.a and R.sup.

Abstract: The invention relates to fullerene derivatives which are capable of scavenging free radicals. The derivatives have the formula F(--X).sub.m (--Y--Z).sub.n, in which F is a fullerene core; each X is independently --CO.sub.2.sup.-, --SO.sub.3.sup.-, --SH, or the like; each --Y--Z is independently (C.sub.3-30 alkyl ether).sub.50 --CH.sub.2 --CO.sub.2.sup.-, (C.sub.3-30 alkyl ester).sub.50 --CH.sub.2 --SO.sub.3.sup.-, (C.sub.3-30 alkyl amide).sub.50 --CH.sub.2 --SH, or the like; m is 0-30; n is 0-30; and the sum of m and n is 2-30.

Abstract: Compounds of the formula ##STR1## in which R.sub.1 is halogen, C.sub.1 -C.sub.3 alkyl, halo-C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy, halo-C.sub.1 -C.sub.3 alkoxy or cyano and/or two substituents R.sub.1 which are bonded to adjacent C atoms of the phenyl ring together are --O--CH.sub.2 --O--; R.sub.2 is hydrogen, halogen or methyl;R.sub.3 is fluorine, chlorine, bromine or C.sub.1 -C.sub.3 alkyl; R.sub.4 is hydrogen or C.sub.1 -C.sub.3 alkyl; either R.sub.5 is hydrogen, C.sub.1 -C.sub.4 alkyl, ##STR2## --COCO--R.sub.8, --CO--R.sub.9 or S(O).sub.m --N(R.sub.10)--COO--R.sub.11 andR.sub.6 is C.sub.1 -C.sub.6 alkyl, halo-C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.6 alkenyl, halo-C.sub.3 -C.sub.4 alkenyl, C.sub.3 C.sub.5 alkynyl, halo-C.sub.3 -C.sub.5 alkynyl, C.sub.1 -C.sub.3 alkoxy-C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.6 cycloalkyl, unsubstituted or substituted phenyl; or R.sub.5 and R.sub.6 together are --(CH.sub.2).sub.4 -- or --(CH.sub.2).sub.5 --; R.sub.7 is hydrogen, halogen or C.sub.1 -C.sub.3 alkyl; R.

Abstract: The invention relates to bis-phosphepines of the formula (I): ##STR1## where: Ar--Ar is biphenyl, 1,1'-binaphthyl or 1-phenylnaphthyl,R.sup.1 independently of one another are F, (C.sub.1 -C.sub.8)-alkyl or (C.sub.1 -C.sub.8)-alkoxy,m is 0, 1, 2, 3 or 4,R.sup.2 and R.sup.3 independently of one another are H, (C.sub.1 -C.sub.20)-alkyl, (C.sub.6 -C.sub.20)-aryl, (C.sub.7 -C.sub.20)-aralkyl, (C.sub.7 -C.sub.20)-alkaryl or (C.sub.3 -C.sub.20)-cycloalkyl andR.sup.4 is (C.sub.1 -C.sub.10)-alkylene, it also being possible for the alkylene chain to contain oxygen atoms and N-alkyl groups, (C.sub.3 -C.sub.10)-cycloalkylene, (C.sub.8 -C.sub.22)-arylene-bisalkyl or (C.sub.6 -C.sub.10)-arylene,the group CR.sup.2 R.sup.3 always being adjacent to the Ar--Ar bond.The invention further relates to processes for the preparation of compounds of the formula (I).

Abstract: Disclosed is a preparation for external application to the skin characterized by containing at least one of benzoic acid derivatives represented by formula (I) or pharmacologically acceptable salts thereof as an active ingredient, the preparation having sufficient sebaceous secretion inhibitory activity with no substantial side effect and high safety for human body. ##STR1## wherein R.sup.1 represents --OH, --OR.sup.3 or --NHR.sup.3 ; R.sup.2 represents a hydrogen atom, a lower alkyl group or a lower acyl group; R represents --O--R.sup.4 or ##STR2## R.sup.3 represents an alkyl group, an alkenyl group or a hydroxyalkyl group; R.sup.4 represents a straight-chain or branched, saturated or mono-unsaturated alkyl group or cycloalkylalkyl group having from 4 to 10 carbon atoms; X represents --O-- or --NH--; and n represents 1 or 2.

Abstract: A method of producing compounds of formula I ##STR1## wherein one of R.sub.1 and R.sub.2 is selected from --OH, --SH, and --NHR.sub.7 ; and the other of R.sub.1 and R.sub.2 is selected from H, --OH, --SH, --NHR.sub.7, and R.sub.8 ; R.sub.3 and R.sub.4 are each independently selected from R.sub.8 ; n and m are each independently 3; and each R.sub.5 and each R.sub.6 is independently selected from --OH, --SH, --NHR.sub.7, and R.sub.8 ; and R.sub.8 is as detailed in the specification;in enantiomerically enriched form, comprising reducing a compound of formula II ##STR2## wherein R.sub.1 -R.sub.6 are defined as in formula I, in the presence of B-haloisopinocampheylborane.